National Immunization Technical Advisory Groups (NITAGs) provide independent, evidence-informed advice to assist their governments in immunization policy formation. However, many NITAGs face challenges in fulfilling their roles. Hence the many requests for formation of a network linking NITAGs together so they can learn from each other. To address this request, the Health Policy and Institutional Development (HPID) Center (a WHO Collaborating Center at the Agence de Médecine Préventive - AMP), in collaboration with WHO, organized a meeting in Veyrier-du-Lac, France, on 11 and 12 May 2016, to establish a Global NITAG Network (GNN). The meeting focused on two areas: the requirements for (a) the establishment of a global NITAG collaborative network; and (b) the global assessment/evaluation of the performance of NITAGs. 35 participants from 26 countries reviewed the proposed GNN framework documents and NITAG performance evaluation. Participants recommended that a GNN should be established, agreed on its governance, function, scope and a proposed work plan as well as setting a framework for NITAG evaluation.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877398PMC
http://dx.doi.org/10.1016/j.vaccine.2017.04.039DOI Listing

Publication Analysis

Top Keywords

global nitag
12
national immunization
8
immunization technical
8
technical advisory
8
advisory groups
8
groups nitags
8
nitag network
8
nitags
5
nitag
5
strengthening sustainability
4

Similar Publications

National immunization technical advisory groups (NITAGs) develop evidence-based vaccination recommendations. Systematic reviews (SRs) are important tools in that process, but conducting them is very resource-intensive. Given the considerable number of immunization-related SRs published and to minimize duplication of effort, a more practical approach for NITAGs is to use existing SRs.

View Article and Find Full Text PDF

Vaccines in the fight against antimicrobial resistance - perspectives from South Africa.

S Afr Med J

September 2024

Division of Medical Microbiology, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.

Antimicrobial resistance (AMR), in which microbes adapt to and resist current therapies, is a well-recognised global problem that threatens to reverse gains made by modern medicine in the last decades. AMR is a complex issue; however, at its core, it is driven by the overuse and inappropriate use of antimicrobials. Socioeconomic factors have been identified as significant contributors to the emergence and exacerbation of AMR, especially in populations facing inadequate access to healthcare, poor sanitation services and high morbidity and mortality rates.

View Article and Find Full Text PDF
Article Synopsis
  • The COVID-19 pandemic caused a significant reduction in influenza virus circulation, leading to the disappearance of the B/Yamagata lineage.
  • This change may impact global influenza epidemiology, requiring updates to surveillance strategies, laboratory safety protocols, and vaccine formulations.
  • In response, the WHO recommended excluding B/Yamagata antigens from future vaccines, highlighting the need for improved global surveillance and collaboration among health stakeholders.
View Article and Find Full Text PDF
Article Synopsis
  • Regulatory agencies and NITAGs evaluate the balance of vaccine benefits and harms, with DQCs (direct quantitative comparisons) being used to support decision-making during the COVID-19 pandemic.
  • The study reviewed 23 publications where DQCs were utilized, revealing their role in various situations, such as new safety signals and changing vaccine contexts.
  • While DQCs provided timely and transparent communication, their reliance on assumptions made them sensitive to changes and limited their applicability to different contexts, especially in the rapidly evolving COVID-19 situation.
View Article and Find Full Text PDF
Article Synopsis
  • Invasive pneumococcal disease (IPD) remains a serious global issue, particularly concerning non-vaccine serotypes, even after the introduction of pneumococcal conjugate vaccines (PCV) in South Africa.
  • The study analyzed over 3,000 IPD genomes from children between 2005-2020, observing a drop in incidence for vaccine-type bacteria in the late-PCV13 period, but some continued to pose a threat.
  • Notably, non-vaccine serotypes showed rising drug resistance and lineage diversity, indicating the need for ongoing genomic surveillance to inform health policies and future vaccine developments.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!